Non-Hodgkin Lymphoma

Manfred Welslau, MD, discusses the rationale of the prospective REFLECT trial with the rituximab biosimilar SDZ-RTX in patients with diffuse large B-cell lymphoma.

Erlene Seymour, MD, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia.

Faculty debate the definitions of chemotherapy resistance, sensitivity, and refractoriness and discussed appropriate management strategies based on how patients would be classified in DLBCL.

Recent trials of novel therapies and therapeutic combinations have introduced promising options for the management of patients with relapsed or refractory diffuse large B-cell lymphoma.

Bruton tyrosine kinase (BTK) inhibitors play an important role in the therapeutic spectrum of B-cell lymphomas.

Grzegorz S. Nowakowski, MD, discusses the rationale for the ongoing, randomized phase 3 ENGINE study in diffuse large B-cell lymphoma.

Brian T. Hill, MD, PhD, discusses the data from the SADAL trial that led to the FDA approval of selinexor for use in patients with diffuse large B-cell lymphoma.

Brad S. Kahl, MD, discusses the current treatment landscape in ​relapsed/refractory indolent non-Hodgkin lymphoma.

Kami J. Maddocks, MD, discusses the tolerability and promise of tafasitamab in combination with lenalidomide in relapsed or refractory DLBCL.

Kami J. Maddocks, MD, discusses the role of tazemetostat in patients with EZH2-mutant follicular lymphoma.

Shuo Ma, MD, PhD, discusses the evolving role of BTK inhibitors in B-cell malignancies, ongoing research efforts examining their use, safety concerns to be aware of with the agents, and next steps for research.

Lori A. Leslie, MD, highlights ibrutinib, acalabrutinib, and zanubrutinib, the 3 FDA approved BTK inhibitors that have become very important weapons in the treatment arsenal for B-cell malignancies.

The European Commission has approved an expanded indication of ibrutinib for use in combination with rituximab in treatment-naïve adult patients with chronic lymphocytic leukemia.

Monica Balzarotti, MD, discusses the current treatment landscape of DLBCL, including the recent FDA approval of selinexor for the treatment of adult patients with relapsed/refractory disease.

Joshua Brody, MD, discusses recent developments in DLBCL treatment, the role of selinexor, and the need for effective biomarkers of response in the space.

A supplemental biologics license application has been filed with the FDA for axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma following 2 or more previous lines of systemic therapy.

Caron Jacobson, MD, discusses the high-risk patient population within relapsed/refractory indolent non-Hodgkin lymphoma included in the phase 2 ZUMA-5 study.

Kami J. Maddocks, MD, discusses emerging therapies in follicular lymphoma.

Brian T. Hill, MD, PhD, sheds light on XPO1 as a target in diffuse large B-cell lymphoma, the emergence of selinexor in the treatment landscape, and exciting agents in the pipeline.